Fernando Rodríguez, the director of CReSA, explains at what stage is the development of the vaccine against ASF.
PhD in Biology (1994), Dr. Rodriguez has devoted his scientific live to explore new avenues to improve vaccinology. His Thesis work was performed at CISA-INIA (Madrid-Spain) working on African swine fever immunology thanks to a Predoctoral thesis from the Bask Government. In 1995 Dr. Rodriguez moved to The Scripps institute (La Jolla, CA, USA) to work as an associate professor in the laboratory of Dr. Lindsay Whitton, first with a postdoctoral fellowship from the Spanish Government and next with another one from the Bask country until the year 2000, when Dr. Rodríguez was promoted to senior associate. During these 5 years at The Scripps Institute, Dr. Rodriguez developed strategies to improve the CD4 and CD8 T-cell responses induced after vaccination, using DNA immunization as a tool. In January 2001 returned to Spain with a FIS contract from the Health Ministry of Spain to work in cancer immunetherapy at the Hospital 12 de Octubre (Madrid). At the end of the year 2003, Dr. Rodríguez moved to CReSA (Barcelona, Spain) with a Ramón y Cajal Contract, later extended with an I3 contract and since then he has been the Principal Investigator of a Research line devoted investigate on African swine fever (ASF). In 2013 Dr. Rodriguez became the coordinator of the exotic diseases Program, today the animal health program from IRTA (Barcelona, Spain).
Dr. Rodríguez authors 80 per-reviewed articles, 4 Patents and has coordinated 9 Research Projects and 5 private Research contracts with National and International companies. Dr. Rodríguez has also supervised 6 Doctoral Thesis.
Since September 2017, Dr. Rodriguez acts as the Scientific Director of CReSA.
Updated CV 23-Oct-2018